NK105 vs Paclitaxel, Phase 3 Breast Cancer Trial
Summary
A Phase 3 clinical trial (NCT01644890) comparing NK105 versus paclitaxel for breast cancer treatment has been registered on ClinicalTrials.gov. The trial is listed under the National Institutes of Health registry with study ID NCT01644890.
About this source
GovPing monitors ClinicalTrials.gov - Phase 3 Oncology Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.
What changed
ClinicalTrials.gov registry entry for a Phase 3 oncology trial. No regulatory obligations or compliance requirements are created by this registration. Trial sponsors and investigators may reference this entry for protocol information.
Affected parties including clinical investigators, healthcare providers, and patients seeking trial participation may consult this registry for enrollment information.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov - Phase 3 Oncology Trials
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov - Phase 3 Oncology Trials publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.